# Exelixis, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Exelixis, Inc). ## Overview Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base. The company also develops next-generation cancer medicines, with zanzalintinib as its lead late-stage pipeline asset, and it partners with companies such as Ipsen and Takeda to extend cabozantinib’s reach outside the United States. ## Products & services • CABOMETYX (cabozantinib) tablets for RCC, HCC and DTC • COMETRIQ (cabozantinib) capsules for medullary thyroid cancer • Cabozantinib royalty revenue from ex-U.S. partners • Collaboration and product supply services • Late-stage oncology pipeline, including zanzalintinib - **Commercial oncology products** (70%) — Approved cabozantinib-based medicines sold in the U.S. for multiple cancer indications. - **Ex-U.S. royalties** (20%) — Royalty income tied to partner sales of cabozantinib outside the U.S. and Japan. - **Collaboration services and supply** (5%) — Development reimbursements, product supply revenue, and deferred revenue recognition from partnerships. - **Pipeline and R&D programs** (5%) — Internal development of zanzalintinib and other oncology candidates that are not yet commercialized. - CABOMETYX tablets for renal cell carcinoma, hepatocellular carcinoma and DTC - COMETRIQ capsules for progressive, metastatic medullary thyroid cancer - Cabozantinib royalties from Ipsen and Takeda outside the U.S. - Product supply and collaboration revenue from licensing arrangements - Zanzalintinib, a late-stage investigational oncology asset ## Customers Exelixis sells primarily to U.S. specialty pharmacies, wholesalers, hospitals and other organizations that dispense oncology medicines to patients. Outside the U.S., its commercial reach depends heavily on partners such as Ipsen and Takeda, which commercialize cabozantinib in their territories and generate royalties for Exelixis. - **U.S. specialty pharmacy and wholesale channel** (primary) — Buys CABOMETYX and COMETRIQ for resale into the oncology care system and is the main commercial route in the U.S. - **Hospitals and oncology providers** (primary) — Receive product through distribution channels and use it in treatment settings for approved cancer indications. - **International partners** (primary) — Ipsen and Takeda commercialize cabozantinib outside the U.S. and pay royalties and other collaboration-related amounts. - **Healthcare professionals** (secondary) — Oncologists, nurses and pharmacists influence prescribing and adoption of cabozantinib therapies. - **Clinical and development collaborators** (secondary) — Partners that support development, supply and commercialization of pipeline and partnered assets. - Specialty pharmacies and wholesalers that distribute CABOMETYX and COMETRIQ - Hospitals and oncology centers that administer the medicines to patients - Oncologists and oncology care teams who prescribe cabozantinib therapies - Ipsen and Takeda as ex-U.S. commercialization partners - Patients with RCC, HCC, DTC and medullary thyroid cancer ## Geography Exelixis is commercially anchored in the United States, where it markets CABOMETYX and COMETRIQ directly. Internationally, the company relies on Ipsen and Takeda to commercialize cabozantinib in more than 60 countries outside the U.S., so ex-U.S. exposure is largely royalty-based rather than direct sales-based. - **United States** (80%) — Direct commercial market for CABOMETYX and COMETRIQ; majority of product revenue. - **Outside the United States** (20%) — Primarily royalty and collaboration revenue from Ipsen and Takeda. - United States is the core direct-sales market for CABOMETYX and COMETRIQ - Ex-U.S. revenue is mainly royalties from partner sales of cabozantinib - CABOMETYX is approved in 67 other countries and commercially available in 68 outside the U.S. - Ipsen and Takeda handle commercialization and distribution in many foreign markets - Manufacturing and supply rely on a global third-party contract network ## Strategy Exelixis is focused on extending the cabozantinib franchise through additional indications, while building zanzalintinib into a new late-stage oncology asset. The company is also broadening its modality mix through partnerships and selective investment, aiming to convert its commercial base into a longer-duration oncology platform. - **Expand cabozantinib indications** (short-term) — New approvals can extend the life of the franchise and support revenue growth from the core asset. - **Advance zanzalintinib** (medium-term) — A successful late-stage launch would diversify the company beyond cabozantinib. - **Leverage partnerships for ex-U.S. commercialization** (medium-term) — Partners provide market access and royalty income without requiring Exelixis to build full international infrastructure. - **Strengthen supply chain and manufacturing redundancy** (short-term) — Reliable product supply is essential for a marketed oncology franchise and future launches. - Maximize cabozantinib in approved and potential new indications - Advance zanzalintinib through late-stage clinical development - Use partnerships to expand global reach and share development risk - Invest selectively across small molecules, biotherapeutics and ADCs - Maintain supply resilience through secondary manufacturing sources ## Risks Exelixis is highly dependent on the commercial performance of CABOMETYX, so any slowdown in uptake, pricing pressure or loss of exclusivity would directly affect revenue. Its pipeline and international economics also depend on clinical success, regulatory approvals and partner execution, while pharmaceutical pricing scrutiny and supply-chain disruption remain important industry-wide risks. - **CABOMETYX concentration risk** [high] — The company states that sales related to cabozantinib account for the majority of revenue, so franchise weakness would have an outsized impact. - **Clinical development and regulatory risk** [high] — Zanzalintinib and additional cabozantinib indications require successful trials and approvals before they can contribute meaningfully. - **Drug pricing and reimbursement pressure** [high] — U.S. healthcare reforms, rebates and formulary restrictions can reduce realized net prices and access. - **Partner dependence outside the U.S.** [medium] — Ex-U.S. commercialization and royalty streams rely on Ipsen and Takeda’s execution and market access. - **Supply chain and manufacturing disruption** [medium] — The company relies on third-party GMP manufacturers and global logistics rather than owned plants. - Heavy dependence on CABOMETYX for revenue and earnings - Clinical and regulatory risk for zanzalintinib and new cabozantinib indications - U.S. drug pricing pressure could reduce net product revenue - Partner execution risk for Ipsen and Takeda outside the U.S. - Manufacturing and supply-chain disruption could affect product availability ## Accounting Revenue recognition is a key judgment area because U.S. product sales are recorded net of rebates, chargebacks, discounts, returns and other allowances that must be estimated before claims are fully known. Collaboration revenue also depends on the timing of milestone payments, deferred revenue release and royalty accounting, which can create quarter-to-quarter volatility and make reported growth uneven. - **Net product revenue allowances** — Net sales and gross-to-net margin - **Collaboration and royalty revenue timing** — Revenue volatility - **Clinical trial and collaboration accruals** — Operating expenses and liabilities - **Stock-based compensation** — Reported operating profit and EPS - Net product revenue depends on estimates for rebates, chargebacks and returns - Royalty revenue from Ipsen and Takeda can move with partner sales - Milestone and deferred collaboration revenue can create lumpy quarterly results - Clinical trial and collaboration accruals require management estimates - Stock-based compensation and income taxes are key non-cash and judgment areas --- *Last updated: 2026-09-24T10:46:56.196846+00:00*